$345.21
0.15% today
NYSE, Apr 02, 09:14 pm CET
ISIN
US40412C1018
Symbol
HCA

HCA Target price 2025 - Analyst rating & recommendation

HCA Classifications & Recommendation:

Buy
68%
Hold
29%
Sell
4%

HCA Price Target

Target Price $379.05
Price $345.73
Potential
Number of Estimates 22
22 Analysts have issued a price target HCA 2026 . The average HCA target price is $379.05. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 28 analysts: 19 Analysts recommend HCA to buy, 8 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the HCA stock has an average upside potential 2026 of . Most analysts recommend the HCA stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 70.60 74.55
8.67% 5.60%
EBITDA Margin 19.63% 19.72%
0.38% 0.46%
Net Margin 7.79% 8.39%
6.77% 7.71%

20 Analysts have issued a sales forecast HCA 2025 . The average HCA sales estimate is

$74.6b
Unlock
. This is
5.60% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$75.9b 7.44%
Unlock
, the lowest is
$73.7b 4.45%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $70.6b 8.67%
2025
$74.6b 5.60%
Unlock
2026
$78.4b 5.11%
Unlock
2027
$82.4b 5.10%
Unlock
2028
$84.9b 3.07%
Unlock
2029
$89.1b 5.00%
Unlock

21 Analysts have issued an HCA EBITDA forecast 2025. The average HCA EBITDA estimate is

$14.7b
Unlock
. This is
6.06% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$14.8b 7.09%
Unlock
, the lowest is
$14.6b 5.18%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $13.9b 9.09%
2025
$14.7b 6.06%
Unlock
2026
$15.4b 5.11%
Unlock
2027
$16.3b 5.26%
Unlock
2028
$16.1b 0.72%
Unlock
2029
$17.0b 5.00%
Unlock

EBITDA Margin

2024 19.63% 0.38%
2025
19.72% 0.46%
Unlock
2026
19.71% 0.05%
Unlock
2027
19.74% 0.15%
Unlock
2028
19.02% 3.65%
Unlock
2029
19.02% 0.00%
Unlock

10 HCA Analysts have issued a net profit forecast 2025. The average HCA net profit estimate is

$6.3b
Unlock
. This is
13.86% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$6.3b 14.83%
Unlock
, the lowest is
$6.2b 12.32%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $5.5b 16.03%
2025
$6.3b 13.81%
Unlock
2026
$7.1b 12.84%
Unlock
2027
$7.9b 11.71%
Unlock

Net Margin

2024 7.79% 6.77%
2025
8.39% 7.71%
Unlock
2026
9.01% 7.39%
Unlock
2027
9.58% 6.33%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 22.00 25.04
16.03% 13.82%
P/E 13.81
EV/Sales 1.76

10 Analysts have issued a HCA forecast for earnings per share. The average HCA EPS is

$25.04
Unlock
. This is
13.87% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$25.25 14.82%
Unlock
, the lowest is
$24.70 12.32%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $22.00 16.03%
2025
$25.04 13.82%
Unlock
2026
$28.25 12.82%
Unlock
2027
$31.56 11.72%
Unlock

P/E ratio

Current 15.72 10.53%
2025
13.81 12.15%
Unlock
2026
12.24 11.37%
Unlock
2027
10.95 10.54%
Unlock

Based on analysts' sales estimates for 2025, the HCA stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.86 8.37%
2025
1.76 5.25%
Unlock
2026
1.68 4.86%
Unlock
2027
1.60 4.86%
Unlock
2028
1.55 2.98%
Unlock
2029
1.47 4.76%
Unlock

P/S ratio

Current 1.21 11.22%
2025
1.14 5.30%
Unlock
2026
1.09 4.86%
Unlock
2027
1.03 4.86%
Unlock
2028
1.00 2.97%
Unlock
2029
0.96 4.76%
Unlock

Current HCA Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B of A Securities
Locked
Locked
Locked Jan 27 2025
Barclays
Locked
Locked
Locked Jan 27 2025
RBC Capital
Locked
Locked
Locked Jan 27 2025
Cantor Fitzgerald
Locked
Locked
Locked Jan 27 2025
Keybanc
Locked
Locked
Locked Jan 07 2025
Truist Securities
Locked
Locked
Locked Jan 06 2025
Morgan Stanley
Locked
Locked
Locked Dec 17 2024
Analyst Rating Date
Locked
B of A Securities:
Locked
Locked
Jan 27 2025
Locked
Barclays:
Locked
Locked
Jan 27 2025
Locked
RBC Capital:
Locked
Locked
Jan 27 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Jan 27 2025
Locked
Keybanc:
Locked
Locked
Jan 07 2025
Locked
Truist Securities:
Locked
Locked
Jan 06 2025
Locked
Morgan Stanley:
Locked
Locked
Dec 17 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today